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Impact of proteinuria and GFR 
on risk of thromboembolism  
in atrial fibrillation
Anticoagulation poses challenges to patients at increased risk for 
bleeding. Patients with chronic kidney disease (CKD) or end-stage 
renal disease have been shown to be at increased risk for bleeding 
events. Many fear that anticoagulation makes arteriovenous access 
for dialysis potentially problematic.
A new study by Go et al. examines the risk of cerebrovascular 
events based on the level of kidney function among persons with 
atrial fibrillation. Patients with an estimated glomerular filtration rate 
(eGFR) greater than 45 ml/min were more likely to have comorbidi-
ties and to have a prior history of stroke, heart failure, hypertension, 
diabetes mellitus, coronary artery disease, or proteinuria. Crude rates 
of thromboembolism were greater among patients with worsening 
kidney function: 1.63, 2.76, and 4.22 events per 100 person-years for 
eGFR ≥60, 45–59, and <45 ml/min, respectively (P<0.001). After 
adjustment for case mix and comorbidities, both eGFR and pro-
teinuria remained significant independent risk factors.
The significance of kidney function in the multivariable model 
indicates that the presence of kidney disease itself imparts an 
increased risk for thromboembolic events. This is important to 
remember as one considers the potential link that is being described 
between matrix 4-carboxyglutamic acid protein (MGP) and vascu-
lar calcification. MGP is a known inhibitor of vascular calcification 
that requires vitamin K for carboxylation and activation. MGP-
deficient transgenic mice develop severe vascular calcification.1 
Similarly, warfarin causes vascular calcification in rats.2 Evidence 
in humans to support a similar link includes a twofold higher aortic 
valve calcification in non-CKD patients on warfarin3 and an associa-
tion between dietary vitamin K intake and both aortic calcification 
and cardiovascular mortality in the general population.4 The role of 
vitamin K and the potential detrimental role of warfarin in patients 
with kidney disease have not been examined and should be watched 
closely. It will be important to quantify the vascular risk that might 
accompany warfarin use and to balance that risk with the natural his-
tory of the disease. (Circulation 2009; 119: 1363–1369; doi:10.1161/
CIRCULATIONAHA.108.816082)
Lynda Szczech
1Genes Dev 1998; 12: 1260–1268. 2Arterioscler Thromb Vasc Biol 2000; 20: 
317–327. 3Blood 2004; 104: 3231–3232. 4J Nutr 2004; 134: 3100–3105.
Donor TLR 4 contributes  
to kidney injury following  
kidney transplantation
Delayed graft function occurs commonly following kidney trans-
plantation, and it is currently believed to be a consequence of 
ischemia/reperfusion (IR) injury. This would explain the higher 
incidence of delayed graft function in deceased-donor allografts 
that routinely endure prolonged periods of ischemia. However, the 
exact mediators of the delayed function remain poorly defined. Toll-
like receptors (TLRs) are a family of cell-surface and intracellular 
proteins initially described as molecular sentinels capable of recog-
nizing pathogen-associated molecular patterns that activate innate 
immunity in response to invading pathogens. Humans express 
more than 10 distinct TLRs that transmit signals through the Toll/
interleukin-1R domain-containing adaptor, inducing interferon 
or myeloid differentiation primary response protein. Downstream 
effects include cytokine and chemokine release, as well as upregula-
tion of costimulatory molecules, which together initiate and amplify 
local inflammation. A growing body of literature suggests that some 
TLRs, including TLR2 and TLR4, function as detectors of sterile (not 
pathogen-associated) injury upon binding to endogenous ligands 
released by damaged cells; heat-shock proteins, high-mobility group 
box-1 protein (HMGB1), heparan sulfate, hyaluronan fragments, 
and fibronectin are examples of endogenous ligands. Other studies 
have also shown that TLR expression is not confined to cells of the 
innate immune system but also occurs in epithelial, endothelial, and 
mesenchymal cells of the kidney, heart, lung, and liver, among oth-
ers. Kidney expression of TLRs is functionally important, as paren-
chymal-cell deficiency of TLR2 or TLR4 dramatically limits kidney 
injury following IR and diminishes the associated intrarenal inflam-
mation. Whether IR injury in humans, particularly in the context of 
kidney transplantation, is also affected by ischemia-induced release 
of damage-associated molecules and subsequent TLR signaling is not 
known. Krüger et al. examined this question and found that TLR4 is 
constitutively expressed within all donor kidneys but is significantly 
higher in deceased-donor than in living-donor organs (Figure). 
Tubules from deceased-donor but not from living-donor kidneys 
also stained positively for HMGB1, a known endogenous TLR4 
ligand. In vitro stimulation of human tubular cells with HMGB1, in 
a TLR4-dependent system, confirmed that HMGB1 can stimulate 
proinflammatory responses through TLR4. To assess the functional 
significance of TLR4 in human kidney transplantation, the authors 
examined whether TLR4 mutations that confer diminished affin-
ity for HMGB1 influence intragraft gene-expression profiles and 
immediate graft function. Compared with kidneys expressing wild-
type alleles, kidneys with a TLR4 loss-of-function allele contained 
less TNF-α and monocyte chemotactic protein-1 and more heme 
oxygenase 1 and exhibited a higher rate of immediate graft function. 
These results represent previously undetected evidence that TLR4 in 
TLR4 expression. TLR4 expression in pre-anastomosis biopsy sections 
from living-donor (LD) and deceased-donor (DD) kidneys. TLR4 was 
expressed in proximal and distal tubules, with higher expression in 
deceased-donor than in living-donor kidneys. 
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the donor kidney contributes to graft inflammation and sterile injury 
following cold preservation and transplantation in humans. Target-
ing TLR4 signaling may have value in preventing or treating pos-
tischemic acute kidney injury after transplantation. (Proc Natl Acad 
Sci USA 2009; 106: 3390–3395; doi:10.1073/pnas.0810169106)
Juan Oliver 
Hypoxia response and VEGF-A  
in renal disease
Proteinuria, inflammation, chronic hypoxia, and rarefaction of 
peritubular capillaries contribute to the progression of renal disease 
by affecting proximal tubular epithelial cells (PTECs). To study 
the transcriptional response that separates patients with a stable 
course from those with a progressive course of disease, Rudnicki 
et al. isolated PTECs by laser capture microdissection from cryocut 
tissue sections of patients with proteinuric glomerulopathies (stable, 
n = 20; progressive, n = 11) with a median clinical follow-up of 26 
months (Figure). Gene-expression profiling and a systems biology 
analysis identified activation of intracellular vascular endothelial 
growth factor (VEGF) signaling and hypoxia response pathways 
in progressive patients, which was associated with upregulation of 
hypoxia-inducible factor (HIF)-1α and several HIF target genes, 
such as transferrin, transferrin receptor, p21, and VEGF receptor 
1, but downregulation of VEGF-A. The inverse expression levels 
of HIF-1α and VEGF-A were significantly superior in predicting 
clinical outcome as compared with proteinuria, renal function, 
and degree of tubular atrophy and interstitial fibrosis at the time of 
biopsy. Interactome analysis showed the association of attenuated 
VEGF-A expression with the downregulation of genes that usually 
stimulate VEGF-A expression, such as epidermal growth factor 
(EGF), insulin-like growth factor-1 (IGF-1), and HIF-2α. In vitro 
experiments confirmed the positive regulatory effect of EGF and 
IGF-1 on VEGF-A transcription in human proximal tubular cells. 
Thus, in progressive but not in stable proteinuric kidney disease, 
human PTECs show an attenuated VEGF-A expression despite an 
activation of intracellular hypoxia response and VEGF signaling 
pathways, which might be due to a reduced expression of positive 
coregulators, such as EGF and IGF-1. (Lab Invest 2009; 89: 337–346; 
doi:10.1038/labinvest.2008.158) 
Marc De Broe
Energy metabolism, lifespan,  
and the renin–angiotensin system
A substantial body of evidence indicates that the renin– 
angio tensin system plays an important role in energy metabolism 
and insulin action. In clinical medicine, blockers of the system 
reduce the incidence of new-onset diabetes. Several animal 
models with alterations in the system have metabolic alterations. 
For example, mice harboring the human renin gene develop 
obesity, and rats overexpressing the mouse Ren-2 gene exhibit 
insulin resistance. Conversely, renin-deficient mice (Ren1c–/–) 
are lean, insulin sensitive, and resistant to diet-induced obes-
ity. In addition, deletion of the angiotensin type 2 receptor 
reduces adipose-cell size and protects from diet-induced obes-
ity and insulin resistance; mice lacking angiotensin-converting 
enzyme have increased energy expenditure, reduced fat mass, 
and improved glucose clearance. 
Two recent studies extend these tantalizing observations. 
In the first, Gratze et al. report that rats harboring the human 
renin gene were consistently heavier than controls and had glu-
cose intolerance.1 Interestingly, these metabolic changes were 
not reversed by an angiotensin-converting enzyme inhibitor, 
a direct renin inhibitor, or a (pro)renin receptor blocker. The 
obese phenotype originated from higher food intake and was 
partly compensated by increases in resting energy expenditure, 
total thermogenesis, and lipid oxidation. These results suggest 
that the renin transgene initiates a process that appears to be 
independent of angiotensin II and leads to increased appetite, 
obesity, and metabolic changes. Amazingly, the mechanisms 
appear to be independent of any currently known renin-related 
effects. In the second study, Benigni et al. report that targeted 
disruption of the Agtr1a gene resulted in marked prolongation 
of lifespan in mice.2 The Agtr1a gene encodes the angiotensin 
type 1A receptor—the major mouse isoform and homologue to 
the single human AGTR1 gene—and its deletion reduced blood 
pressure. The average lifespan of Agtr1a–/– animals and wild-type 
littermates was 31 and 25 months, respectively. Food intake and 
body size were similar between Agtr1a–/– and wild-type mice. 
Interestingly and somewhat surprisingly, the heart weight/body 
weight ratio and left ventricular mass were comparable between 
Agtr1a–/– and wild-type mice. However, myocytes were smaller 
and there was less cardiac fibrosis in Agtr1a–/– mice. Urine 
protein excretion and plasma blood urea nitrogen were com-
parable between the two groups. Finally, multiple organs from 
the Agtr1a–/– mice displayed less oxidative damage than those 
of wild-type mice. Whether these changes and their effect on 
lifespan are due to changes in blood pressure, metabolic effects, 
or both is unresolved. While both studies raise more questions 
than they provide answers, they startlingly display that much 
more remains to be discovered about the renin–angiotensin 
system, one of the best-understood homeostatic regulatory sys-
tems. (1Hypertension 2009; 53: 516–523; doi:10.1161/HYPER-
TENSIONAHA.108.124966. 2J Clin Invest 2009; 119: 524–530; 
doi:10.1172/JCI36703)
Juan Oliver
Immunostaining for VEGF in stable (upper panels) and progressive 
patients (lower panels).
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